

Press Release

Clinical data of Medigene's dendritic cell (DC) vaccines in prostate cancer to be presented at AACR conference

Martinsried/Munich, 17 March 2016. [Medigene AG](#) (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, announces that the academic group of Prof. Gunnar Kvalheim at the Department of Cellular Therapy at the Oslo University Hospital, Norway, will present preliminary clinical phase I/II data on dendritic cell (DC) vaccines for the treatment of prostate cancer utilising Medigene's DC vaccine technology at the upcoming American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA, USA from 16 - 20 April 2016.

The poster entitled "Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin" will be presented during the poster session on *Adoptive Cell Therapy, Immune Checkpoints, and Vaccines* on Monday, 18 April, providing data from an ongoing investigator-initiated trial (IIT) conducted at the Oslo University Hospital.

More detailed information can be found in the abstract under the following link:

<http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=ac456e79-efd5-416e-a7de-67382c67723a&cKey=2ab5cd11-b3d8-40a8-8087-b0c57f2e8034&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267>

Presentation Time: Monday, April 18, 2016, 1:00 PM - 5:00 PM

Location: Section 21

Poster Board Number: 27

The Oslo University Hospital has an agreement with Medigene for use of Medigene's new generation DC vaccines for their ongoing academic clinical studies.

About Medigene's DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies. Currently, Medigene evaluates its DC vaccines in a company-sponsored phase I/II clinical trial in acute myeloid leukaemia (AML). Further studies utilising Medigene's DC vaccine technology include two ongoing clinical investigator-initiated trials (IITs): a clinical phase I/II trial for treating acute myeloid leukaemia (AML) at Ludwig Maximilians University Hospital Grosshadern, Munich, and a clinical phase II trial of a treatment for prostate cancer at Oslo University Hospital. Moreover, compassionate use patients are treated with DC vaccines at the Department of Cellular Therapy at Oslo University Hospital.

Dendritic cells (DCs) are the most potent antigen presenting cells of our immune system. Their task is to take up, process and present antigens on their cell surface, which enables them to activate antigen-specific T cells for maturation and proliferation. This way T cells can recognise and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to attack tumour cells. The team of Medigene Immunotherapies GmbH's scientists has developed new, fast and efficient methods for generating dendritic cells ex-vivo, which have relevant characteristics to activate both T cells and NK cells. The DC vaccines are developed from autologous (patient-derived) precursor cells, isolated from the patient's blood, and can be loaded with tumour-specific antigens to treat different types of cancer. Medigene's DC vaccines

are in development for the treatment of minimal residual disease or use in combination therapies.

Further audio-visual education about Medigene's DC-Vaccines at:

<https://vimeo.com/123005832>

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer

Tel.: +49 - 89 - 20 00 33 - 33 01

Email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.